Business Context and Reporting Period
This Form 8-K is a current report filed by Immudyne, Inc. (not Lifemd, Inc.) on October 12, 2017, covering events occurring on October 1, 2017. The filing reports the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Dr. Michael Borenstein to the Board of Directors. Dr. Borenstein is a board-certified dermatologist with a Ph.D. in molecular and cellular pharmacology. He entered into a customary director agreement with a three-year term.
Compensation and Agreements
- Equity Grant: Dr. Borenstein received a fully vested option for 100,000 shares of common stock.
- Exercise Price: $0.35 per share.
- Performance Conditions: Additional options may be granted upon the Company achieving certain pre-tax revenue thresholds as specified in the agreement.
- Related Party Transactions: The filing states there are no reportable related party transactions or family relationships between Dr. Borenstein and existing directors or officers.
Investor Verification Checklist
- Verify the full text of the Director Agreement (Exhibit 10.1) to confirm specific pre-tax revenue thresholds required for additional option grants.
- Confirm the total number of outstanding options and the dilution impact of the 100,000 newly granted shares.
- Review the Company's current cash position to assess the ability to meet future revenue targets or operational needs, as no financial data is included in this filing.